Numis Securities Ltd reiterated their buy rating on shares of Indivior PLC (LON:INDV) in a research report released on Friday, September 15th. Numis Securities Ltd currently has a GBX 470 ($6.32) price target on the specialty pharmaceutical company’s stock.
Several other research analysts also recently commented on the stock. Citigroup Inc. reissued a neutral rating and set a GBX 280 ($3.77) price objective on shares of Indivior PLC in a report on Tuesday, September 5th. Jefferies Group LLC reissued a buy rating and set a GBX 490 ($6.59) price objective on shares of Indivior PLC in a report on Wednesday, June 7th. Royal Bank Of Canada reissued an outperform rating and set a GBX 470 ($6.32) price objective on shares of Indivior PLC in a report on Thursday, August 3rd. Finally, Stifel Nicolaus reissued a buy rating and set a GBX 400 ($5.38) price objective on shares of Indivior PLC in a report on Friday, September 15th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of GBX 395.50 ($5.32).
Shares of Indivior PLC (INDV) opened at 329.00 on Friday. Indivior PLC has a 52-week low of GBX 246.50 and a 52-week high of GBX 421.50. The firm’s 50-day moving average price is GBX 367.14 and its 200-day moving average price is GBX 335.73. The stock’s market cap is GBX 2.37 billion.
WARNING: This news story was first reported by BBNS and is the property of of BBNS. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/indivior-plc-indv-given-buy-rating-at-numis-securities-ltd/1646772.html.
About Indivior PLC
Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.
Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with our FREE daily email newsletter.